[Laser flare photometry for identification of high-risk patients for proliferative vitreoretinopathy]. / Laser Flare Photometrie zur Identifizierung von Hochrisikopatienten für proliferative Vitreoretinopathie.

Proliferative vitreoretinopathy (PVR) is a complication of rhegmatogenous retinal detachment and trauma, which occurs in approximately 10% following vitreoretinal surgery. The visual prognosis for established PVR is poor and so far there is no established conservative treatment for PVR. In the currently recruiting PRIVENT trial the aim is to find a prophylactic treatment possibility for PVR. The PRIVENT study examines the influence of intraoperative adjuvant pharmacotherapy on reducing the incidence of PVR; however, this requires the identification of eyes with increased risk for PVR. Laser flare photometry is a simple method to predict the individual risk for PVR. It is a non-invasive technique that objectifies the Tyndall effect. Various laser flare meter devices are available on the market. In previous studies it could be shown that laser flare photometry can predict the development of PVR in eyes with primary rhegmatogenous retinal detachment with a sensitivity of 80%. The identification of these high-risk eyes for PVR could be the first step towards solving the problem of PVR.

[Tumor and pulmonary cysts - Lice, fleas or both?]. / Tumor und Zysten in der Lunge - Läuse, Flöhe oder beides?

The article reports on a 60-year-old female patient with insulin-dependent diabetes who presented with coughing, chest pains and low-grade fever. Auscultation revealed a vesicular breathing noise bilaterally and the laboratory results showed slightly increased infection parameters. The initial diagnostic work-up included chest x-ray and contrast-enhanced computed tomography (CT). The diagnostics resulted in a pulmonary adenocarcinoma with osseous and hepatic metastases. Furthermore, widespread bilateral pulmonary cystic lesions were observed. Regarding the wide spectrum of differential diagnoses and the clinical pattern, the findings have to be regarded as cystic metastases and not as primary cystic lung disease.

Intranasal application of the melanocortin 4 receptor agonist MSH/ACTH(4-10) in humans causes lipolysis in white adipose tissue.

OBJECTIVE: The melanocortin system has a highly significant role in the hypothalamic regulation of body weight and energy expenditure. In animals, intracerebroventricular infusion of melanocortin receptor 4 (MCR-4) agonists increases basal metabolic rate through activation of the sympathetic nervous system and subsequently reduces food intake. In humans, direct access of MCR-4 agonists to the central nervous system can be achieved by a transnasal route, which leads to weight loss with chronic administration. In the present study, we aimed at investigating the effects of intranasally administered MC4-R agonist MSH/ACTH(4-10) on lipolysis and sympathetic nervous system activity in healthy humans. DESIGN: Healthy normal weight, male volunteers (n=10) received either 10 mg MSH/ACTH(4-10) or placebo intranasally in a double-blinded randomized crossover design. Interstitial glycerol release was assessed by microdialysis in abdominal white adipose tissue (WAT) and in skeletal muscle (SM) of the forearm. Local blood flow, systemic blood pressure, heart rate and muscle sympathetic nerve activity (MSNA) within the superficial peroneal nerve were recorded at rest and after nitroprusside infusion. RESULTS: At 45 min after MSH/ACTH(4-10) administration WAT glycerol concentrations increased by 53.4±19.3% compared with baseline conditions (P<0.05) and remained significantly higher throughout the experiment when compared with placebo (P<0.05) while local glycerol release in SM was not significantly affected. Resting MSNA was not altered by MSH/ACTH(4-10) administration; however, sympathoexcitation by intravenous nitroprusside was markedly elevated (MSH/ACTH(4-10) 569±69% increase to baseline; placebo: 315±64%; P<0.01). CONCLUSION: Intranasally administered MCR-4 agonist MSH/ACTH 4-10 increases both subcutaneous WAT lipolysis and MSNA, which suggests a direct central nervous peptide effect in humans on key factors of human energy metabolism.